A Study of S-740792 in Healthy Adult Study Participants
← catalyst calendarSponsored by Shionogi (industry) · 4507.T — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
99actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-21 | actual | When the study began enrolling |
| Primary completion | 2025-09-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-24 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: S-740792 Suspension
- Drug: Midazolam
- Drug: Placebo
- Drug: S-740792 Tablet
Primary outcomes
what the primary-completion date above is the date OFParts 1 and 2: Number of Participants Experiencing Treatment-emergent Adverse Events
measured Day 1 through Day 28
Part 3: Plasma Concentration of S-740792
measured Day 1 (pre-administration, up to 144 hours post-administration) of periods 1-3 (10 days/period)
Part 3: Time to Maximum Plasma Concentration (Tmax) of S-740792
measured Day 1 (pre-administration, up to 144 hours post-administration) of periods 1-3 (10 days/period)
Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed